Indication
For treatment of 5q spinal muscular atrophy (SMA).
Medicine details
- Medicine name:
- nusinersen (Spinraza)
- SMC ID:
- SMC2805
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Ultra-orphan reassessment
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 30 June 2025